13,707 results match your criteria Cutaneous T-Cell Lymphoma


Retrospective Analysis of 118 Patients With Cutaneous T-Cell Lymphomas: A Single-Center Experience.

Front Oncol 2022 7;12:884091. Epub 2022 Jun 7.

First Dept. of Internal Medicine - Hematology, University General Hospital in Prague and First Faculty of Medicine, Charles University, Prague, Czechia.

Cutaneous T-cell lymphomas (CTCL) represent rare non-Hodgkin lymphomas (NHL) with an incidence less than 1 per 100,000 inhabitants. The most common type of CTCL is mycosis fungoides (MF), which represents approximately 60% of all CTCL, followed by Sézary syndrome (SS), approximately 5%. We retrospectively analyzed the outcome of 118 patients with MF (n=96) and SS (n=22) treated between the years 1998 and 2021 at the Charles University General Hospital in Prague, Czech Republic. Read More

View Article and Full-Text PDF

Combined High-Throughput Approaches Reveal the Signals Driven by Skin and Blood Environments and Define the Tumor Heterogeneity in Sézary Syndrome.

Cancers (Basel) 2022 Jun 9;14(12). Epub 2022 Jun 9.

Istituto Dermopatico dell'Immacolata, IDI-IRCCS, Via dei Monti di Creta, 104, 00167 Rome, Italy.

Sézary syndrome (SS) is an aggressive variant of cutaneous t-cell lymphoma characterized by the accumulation of neoplastic CD4+ lymphocytes-the SS cells-mainly in blood, lymph nodes, and skin. The tumor spread pattern of SS makes this lymphoma a unique model of disease that allows a concurrent blood and skin sampling for analysis. This review summarizes the recent studies highlighting the transcriptional programs triggered by the crosstalk between SS cells and blood-skin microenvironments. Read More

View Article and Full-Text PDF

Epidermotropic cutaneous T-cell lymphoma with follicular helper T-cell phenotype limited to one anatomical region.

J Dermatol 2022 Jun 17. Epub 2022 Jun 17.

Department of Dermatology, St. Marianna University School of Medicine, Kawasaki, Japan.

View Article and Full-Text PDF

Deepening the observation of mycosis fungoides through dermoscopy: definition of the dermoscopic profiles of its progression stages and variants.

Authors:
A Borghi

J Eur Acad Dermatol Venereol 2022 07;36(7):946

Section of Dermatology and Infectious Diseases, University of Ferrara, Ferrara, Italy.

View Article and Full-Text PDF

Immune signatures of CD4 and CD68 predicts disease progression in cutaneous T cell lymphoma.

Am J Transl Res 2022 15;14(5):3037-3051. Epub 2022 May 15.

Department of Hematology, Peking University Shenzhen Hospital Shenzhen 518000, Guangdong, P. R. China.

Background: Cutaneous T-cell lymphoma (CTCL) is highly heterogeneous, and its prognosis is closely related to the disease stage. The tumor microenvironment (TME) is an important component of tumor tissue, driving cancer cell growth, progression, and metastasis. However, the diagnostic value of TME in CTCL has not yet been studied in-depth. Read More

View Article and Full-Text PDF

A new challenge area for cutaneous lymphomas.

Authors:
M Bagot

Presse Med 2022 03;51(1):104129

Service de Dermatologie, Hôpital Saint-Louis, AP-HP, 1 avenue Claude Vellefaux, Paris 75010, France; INSERM U976, Institut de Recherche Saint-Louis, 1 avenue Claude Vellefaux, Paris 75010, France; Université Paris Cité, Paris, France; Réseau National INCa Lymphomes Cutanés; Groupe Français d'Etude des Lymphomes Cutanés. Electronic address:

View Article and Full-Text PDF

Advanced-Stage CD30 Mycosis Fungoides Treated With Brentuximab.

Actas Dermosifiliogr 2022 05 10;113(5):529-531. Epub 2021 Nov 10.

Servicio de Dermatología, Hospital Universitario 12 de Octubre, Universidad Complutense de Madrid, Madrid, España.

View Article and Full-Text PDF

Pralatrexate for Peripheral T-cell lymphoma (PTCL): Chance only supports the prepared mind. Systematic review.

Anticancer Agents Med Chem 2022 Jun 10. Epub 2022 Jun 10.

University of Health Sciences, Institute of Health Sciences, Department of Molecular Oncology, Istanbul, Turkey.

Background: Due to their primary effects on DNA synthesis, antimetabolites are most effective against actively dividing cells and significantly specific to the cell cycle phase. Pralatrexate (PDX), an antifolate metabolite designed to accumulate in cancer cells, was the first new agent approved by the US Food and Drug Administration for the treatment of resistant/recurrent peripheral T-cell lymphomas. PDX was a drug that is frequently used not only for PTCL, but also for cutaneous T-cell lymphoma (CTCL), extranodal natural killer (NK) / T-cell lymphoma. Read More

View Article and Full-Text PDF

HTLV, a multi organ oncovirus.

Microb Pathog 2022 Jun 7:105622. Epub 2022 Jun 7.

Inflammation and Inflammatory Diseases Research Center, Mashhad University of Medical Sciences, Iran. Electronic address:

Human T lymphotropic virus (HTLV-I) is a retrovirus that has been recognized as a causative agent of two crucidal diseases, HTLV-I-Associated Myelopathy/Tropical Spastic Paraparesis (HAM/TSP) and Adult T cell Leukemia-Lymphoma (ATLL). The virus not only induces those diseases in a small proportion of HTLV-I carriers (3-5%) but also it is associated with other diseases such as HTLV-I-Associated Arthropathy (HAAP), Cutaneous T Cell Lymphoma (CTCL), Graves' disease, uveitis, polymyositis, chronic respiratory diseases, lymphadenitis and dermatitis. Furthermore, HTLV related and accelerated disorders were more investigated, and the factors that might implicate in the development or progression of diseases have been discussed. Read More

View Article and Full-Text PDF

Characterization of primary cutaneous T-cell lymphoma following solid organ transplantation.

Int J Dermatol 2022 Jun 10. Epub 2022 Jun 10.

Department of Dermatology, Mayo Clinic, Jacksonville, FL, USA.

Background: Immunosuppression following solid organ transplantation is a known risk factor for the development of posttransplant lymphoproliferative disorders (PTLD). Primary cutaneous T-cell lymphoma (CTCL) occurring in the posttransplant setting is rare, which has made comprehensive understanding of this disease challenging. This study aims to further characterize the spectrum of clinicopathologic features of CTCL in solid organ transplant recipients (SOTR). Read More

View Article and Full-Text PDF

Adjusting for treatment crossover in the MAVORIC trial: survival in advanced mycosis fungoides and Sézary syndrome.

J Comp Eff Res 2022 Aug 9;11(11):805-813. Epub 2022 Jun 9.

Payer Value and Patient Access, Kyowa Kirin, Marlow, SL7 1HZ, UK.

Relative overall survival (OS) estimates reported in the MAVORIC trial are potentially confounded by a high proportion of patients randomized to vorinostat switching to mogamulizumab; furthermore, vorinostat is not used in clinical practice in the UK. Three methods were considered for crossover adjustment. Survival post-crossover adjustment was compared with data from the Hospital Episode Statistics (HES) to contextualize estimates. Read More

View Article and Full-Text PDF

Mitigation strategies among cutaneous T-cell lymphoma patients with positive skin and soft tissue cultures have unclear impacts on the risk of subsequent bacteremia.

Leuk Lymphoma 2022 Jun 7:1-8. Epub 2022 Jun 7.

Department of Hematology and Medical Oncology, Winship Cancer Institute, Emory University, Atlanta, GA, USA.

Infections originating in the skin/soft tissue are a major cause of mortality in cutaneous T-cell lymphoma (CTCL). We performed a retrospective analysis to characterize cutaneous cultures and assess risk factors for bacteremia among 69 patients with CTCL. Cutaneous infections and antimicrobial resistance were common. Read More

View Article and Full-Text PDF

CD4/CD8 double-negative mycosis fungoides with large cell transformation and involvement of the lungs and leptomeninges.

Dermatol Online J 2022 Mar 15;28(2). Epub 2022 Mar 15.

The University of Texas Health Science Center, McGovern Medical School, Houston, Texas, USA,.

Mycosis fungoides (MF), the most common cutaneous T-cell lymphoma, classically has an indolent clinical course, with lesions slowly progressing from patch to plaque to tumor stage. In some cases, the late stages of disease involve extra-cutaneous dissemination to lymph nodes or viscera. Although this "Alibert-Bazin" type is the prototypic MF, there are several variants and subtypes of MF that may have different clinical implications for treatment and prognosis. Read More

View Article and Full-Text PDF

Lifestyle, demographic and Skindex measures associated with cutaneous T-cell lymphoma: a single institution cohort study.

Arch Dermatol Res 2022 Jun 6. Epub 2022 Jun 6.

Department of Dermatology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

Cutaneous T-cell lymphoma (CTCL) risk factors and associated quality of life are poorly understood. Previous studies of CTCL risk factors explored patient comorbidities and lifestyle exposures, but not in conjunction with disease stage, subtype, severity, or health-related quality of life (HRQoL). We investigated lifestyle exposures and demographic factors associated with advanced-stage disease, increased disease severity, and poorer HRQoL outcomes in this single-center cohort study. Read More

View Article and Full-Text PDF

Cost-Effectiveness of Extracorporeal Photopheresis for the Treatment of Patients With Erythrodermic (Stage T, M) Cutaneous T-Cell Lymphoma in the Australian Setting.

Value Health 2022 Jun 11;25(6):965-974. Epub 2022 Jan 11.

Health Technology Analysts, Sydney, New South Wales, Australia; The George Institute for Global Health, Sydney, New South Wales, Australia; The University of New South Wales, Sydney, New South Wales, Australia. Electronic address:

Objectives: Cutaneous T-cell lymphoma (CTCL) is a rare and incurable disease, and patients currently experience a lack of treatment options in Australia. This analysis evaluated the cost-effectiveness of extracorporeal photopheresis (ECP) compared with standard of care therapy for the treatment of patients with erythrodermic (stage T, M) CTCL, who are refractory to previous systemic treatment.

Methods: A Markov model was developed from the perspective of the Australian government. Read More

View Article and Full-Text PDF

Health-related quality of life in cutaneous T-cell lymphoma: A cross-sectional survey study.

Skin Health Dis 2021 Sep 15;1(3):e45. Epub 2021 May 15.

Clinical Research Division Fred Hutchinson Cancer Research Center Seattle Washington USA.

Background: Patients with cutaneous T-cell lymphoma (CTCL) often have indolent but symptomatic disease.

Objective: Assessment of the health-related quality of life (HRQoL) of patients with CTCL.

Methods: Cross-sectional survey study. Read More

View Article and Full-Text PDF
September 2021

A rare case of aggressive cytotoxic T-cell lymphoma in a patient on dupilumab.

JAAD Case Rep 2022 Jun 10;24:112-114. Epub 2022 May 10.

Department of Dermatology, The University of Texas Medical Branch, Galveston, Texas.

View Article and Full-Text PDF

Angioimmunoblastic T-cell Lymphoma Mimicking DRESS Syndrome.

Cutis 2022 Mar;109(3):E29-E32

Department of Dermatology, Naval Medical Center, Camp Lejeune, North Carolina.

Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma arising from follicular T-helper cells. Cutaneous findings and nonspecific systemic symptoms often associated with this malignancy can closely resemble those of more common entities, such as a viral exanthem or drug eruption, depending on the history and context. These similarities in presentation to more common entities can cause a delay in the diagnosis of AITL and subsequent initiation of treatment, which has considerable implications for morbidity and mortality. Read More

View Article and Full-Text PDF

Morphology of Mycosis Fungoides and Sézary Syndrome in Skin of Color.

Cutis 2022 Mar;109(3):E3-E7

Department of Dermatology, Feinberg School of Medicine, Northwestern University, Chicago, Illinois.

Although mycosis fungoides (MF) and Sézary syndrome (SS) commonly affect Black patients, dermatologic educational resources primarily describe the appearance of these conditions in lighter skin types. Skin of color (SoC) patients with Fitzpatrick skin types (FSTs) IV to VI tend to have variable morphologies compared to the erythematous patches, plaques, or tumors in non-sun-exposed areas seen in non-SoC patients (FSTs I-III). We performed a single-institution review of clinical photographs of patients with FSTs I to VI with the primary outcome of determining the frequency of various morphologic features of MF/SS in SoC vs non-SoC patients. Read More

View Article and Full-Text PDF

A Case of Cutaneous T Cell Lymphoma Masquerading as Keloidal Blastomycosis Treated with CHOP Regimen.

Indian J Dermatol 2022 Jan-Feb;67(1):84-86

Department of Dermatology, Venereology and Leprosy, Sree Balaji Medical College and Hospital, Chennai, Tamil Nadu, India E-mail:

View Article and Full-Text PDF

"Alterations in the Skin Microbiota Are Associated With Symptom Severity in Mycosis Fungoides".

Front Cell Infect Microbiol 2022 17;12:850509. Epub 2022 May 17.

Department of Malignant Hematology, Moffitt Cancer Center, Tampa, FL, United States.

Cutaneous T cell lymphoma (CTCL), a non-Hodgkin lymphoma, is thought to arise from mature tissue-resident memory T cells. The most common subtypes include Mycosis Fungoides and Sezary Syndrome. The role of skin microbiota remains unclear in the symptom manifestation of MF. Read More

View Article and Full-Text PDF

Activity and safety of topical pimecrolimus in patients with early stage mycosis fungoides (PimTo-MF): a single-arm, multicentre, phase 2 trial.

Lancet Haematol 2022 Jun;9(6):e425-e433

Department of Pathology, Fundación Jiménez Díaz, Madrid, Spain.

Background: The calcineurin pathway is often activated in mycosis fungoides. We aimed to assess the activity and safety of topical pimecrolimus, a calcineurin inhibitor, in patients with early mycosis fungoides.

Methods: PimTo-MF was a single-arm, multicentre, phase 2 trial done at six medical centres in Spain. Read More

View Article and Full-Text PDF

Future role of topical pimecrolimus in early stage mycosis fungoides?

Lancet Haematol 2022 06;9(6):e389-e391

University Hospital Birmingham, Birmingham B15 2TH, UK. Electronic address:

View Article and Full-Text PDF

Hyper-IgE and Carcinoma in CADINS Disease.

Front Immunol 2022 16;13:878989. Epub 2022 May 16.

Department of Pediatrics, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany.

Background: Atopic dermatitis (AD) affects up to 25% of children and 10% of adults in Western countries. When severe or recurrent infections and exceedingly elevated serum IgE levels occur in AD patients, an inborn error of immunity (IEI) may be suspected. The International Union of Immunological Societies classification lists variants in different genes responsible for so-called Hyper-IgE syndromes. Read More

View Article and Full-Text PDF

Association of Flame-Retardant Clothing With Mycosis Fungoides: A Retrospective Analysis.

Dermatol Pract Concept 2022 May 1;12(2):e2022091. Epub 2022 Apr 1.

Department of Dermatology, University of Texas, MD Anderson Cancer Center, Houston, Texas, USA.

Introduction: Mycosis fungoides (MF), the most prevalent form of cutaneous T-cell lymphoma (CTCL), has been associated with a variety of environmental and occupational exposures. Flame-retardant clothing (FRC), in contrast to flame-resistant clothing, is chemically treated and may constitute a previously unrecognized occupational hazard.

Objectives: To report an association between FRC and MF. Read More

View Article and Full-Text PDF

Primary Cutaneous Gamma-Delta T-Cell Lymphoma Initially Diagnosed as Subcutaneous Panniculitis-like T-Cell Lymphoma with Dermatomyositis.

Dermatopathology (Basel) 2022 Apr 29;9(2):143-147. Epub 2022 Apr 29.

Department of Dermatology, Osaka City University Graduate School of Medicine, Osaka 545-8585, Japan.

Primary cutaneous gamma-delta T-cell lymphoma (CGD-TCL) is a rare cutaneous lymphoma. Panniculitis-like T-cell lymphoma (SPTCL) has a better prognosis than CGD-TCL. SPTCL is sometimes associated with autoimmune disease. Read More

View Article and Full-Text PDF

Erythematous, telangiectatic nodule within the melomental fold.

JAAD Case Rep 2022 Jun 23;24:64-67. Epub 2022 Apr 23.

C.W. Bill Young Department of Veterans Affairs Medical Center, Bay Pines, Florida.

View Article and Full-Text PDF